newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

ALGS
  • Aligos Therapeutics (NASDAQ: ALGS) announced positive data from two presentations at the CROI conference held Feb. 22–25, 2026, in Denver, Colorado.
  • The first presentation detailed Phase 1 monotherapy study results for pevifoscorvir sodium, a CAM-E for chronic hepatitis B virus (HBV) infection.
  • The second presentation showcased pharmacokinetics data for ALG-097558, a ritonavir-free pan-coronavirus protease inhibitor, in participants with hepatic and renal impairment.
  • The ALG-097558 project received funding from the National Institute of Allergy and Infectious Diseases (NIAID) under Contract No. 75N93023C00052.
  • CEO Lawrence Blatt highlighted the company's progress with both the HBV program and its government-funded COVID-19 initiatives.
  • The pevifoscorvir sodium poster (Title: High Viral Suppression in Chronic HBV Infection Subjects with Pevifoscorvir Sodium Monotherapy) was presented by Stanley Wang, MD, on Feb. 23, 2026.
  • The ALG-097558 poster (Title: Pharmacokinetics of ALG-097558, a Pan-Coronavirus 3CL-Pro Inhibitor, in Renal and Hepatic Impairment) was presented by Megan Fitzgerald, PhD, on Feb. 25, 2026.
  • Presentation details will be available on the Aligos website after the live event.
  • Aligos is a clinical-stage biopharmaceutical company focused on liver diseases, including HBV, MASH, obesity, and coronaviruses.